The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium

MLA

Lewis B. Silverman, et al. “The Low Incidence of Secondary Acute Myelogenous Leukaemia in Children and Adolescents Treated with Dexrazoxane for Acute Lymphoblastic Leukaemia: A Report from the Dana-Farber Cancer Institute ALL Consortium.” European Journal of Cancer, vol. 47, June 2011, pp. 1373–79. EBSCOhost, https://doi.org/10.1016/j.ejca.2011.03.022.

APA

Lewis B. Silverman, Peter D. Cole, Kristen E. Stevenson, Luis A. Clavell, Lynda M. Vrooman, Uma H. Athale, Stephen E. Sallan, Donna Neuberg, Kara M. Kelly, Harvey J. Cohen, Marshall A. Schorin, Caroline Laverdière, Barbara L. Asselin, Bruno Michon, Eric Larsen, Cindy L. Schwartz, & Steven E. Lipshultz. (2011). The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: A report from the Dana-Farber Cancer Institute ALL Consortium. European Journal of Cancer, 47, 1373–1379. https://doi.org/10.1016/j.ejca.2011.03.022

Chicago

Lewis B. Silverman, Peter D. Cole, Kristen E. Stevenson, Luis A. Clavell, Lynda M. Vrooman, Uma H. Athale, Stephen E. Sallan, et al. 2011. “The Low Incidence of Secondary Acute Myelogenous Leukaemia in Children and Adolescents Treated with Dexrazoxane for Acute Lymphoblastic Leukaemia: A Report from the Dana-Farber Cancer Institute ALL Consortium.” European Journal of Cancer 47 (June): 1373–79. doi:10.1016/j.ejca.2011.03.022.